
    
      -  Treatment duration was 24 weeks in total.

        -  However, at Week 12, all participants on placebo and the participants on the 50 mg dose
           who had not achieved 20% improvement in swollen joint count (SJC66) and tender joint
           count (TJC68) were assigned (automatically via interactive web response system (IWRS))
           to 100 mg once daily (QD) in a blinded fashion and continued treatment until Week 24.

        -  Participants in the other groups maintained their randomized treatment until Week 24.
    
  